Formycon AG (FSE: FYB) and OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) announced a strategic manufacturing partnership for biosimilars, combining Formycon's development expertise with OneSource's integrated manufacturing capabilities. Under the deal, OneSource will serve as a strategic manufacturing partner, providing Drug Substance (DS) and Drug Product (DP) manufacturing from its biologics facility in Bangalore, India. This collaboration is a key component of Formycon's FYB4Growth strategy, which emphasizes cost-efficiency and operational excellence.
Dr. Stefan Glombitza, CEO of Formycon AG, stated: "Reliable, scalable and cost-efficient manufacturing is a cornerstone of our FYB4Growth strategy. By adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities with a partner that meets our unwavering commitment to high standards of quality, operational excellence and cost-efficiency." The partnership aims to broaden sustainable global access to life-changing biosimilar therapies.
Neeraj Sharma, Managing Director & CEO of OneSource Specialty Pharma, commented: "We are delighted to partner with Formycon, one of the world's leading biosimilar developers with a proven track record of bringing high-quality biosimilars to global markets. This partnership brings together Formycon's development expertise and OneSource's integrated manufacturing capabilities to expand access to high-quality, affordable biologics for patients worldwide." He added that the partnership reinforces the belief that India is uniquely positioned as a global hub for biologics development and manufacturing.
The collaboration addresses the growing demand for biosimilars, which are critical for reducing healthcare costs and expanding patient access. According to the press release, by 2032, many biopharmaceutical drugs will lose patent protection, including 45 blockbusters with an estimated annual global turnover of over $200 billion. Global biosimilar sales currently amount to around $21 billion and are projected to rise to over $74 billion by 2030. This partnership positions both companies to capitalize on this market growth.
OneSource brings a strong track record with five manufacturing facilities approved by leading global regulatory authorities, including the US FDA and EMA, and expertise across biologics, sterile injectables, and drug-device combinations. Formycon, a leading independent biosimilar developer, has three biosimilars on the market—FYB201/ranibizumab, FYB202/ustekinumab, and FYB203/aflibercept—and four pipeline candidates including FYB206/pembrolizumab and FYB208/dupilumab. The partnership leverages OneSource's end-to-end biologics manufacturing to support Formycon's pipeline for global markets.
This strategic alliance is significant for the pharmaceutical industry as it demonstrates a model for cost-effective biosimilar production. By utilizing OneSource's capabilities in India, the partnership can achieve lower manufacturing costs, which is essential for making biosimilars affordable in emerging markets. The FYB4Growth strategy, detailed on fyb4growth.com, includes geographic diversification into high-growth regions such as MENA, APAC, and Latin America, which will benefit from this partnership.
Furthermore, the partnership underscores the importance of reliable supply chains in the biosimilar space. As biosimilars face competition from originator biologics and other biosimilars, manufacturing efficiency becomes a key differentiator. OneSource's integrated platform, from cell line development to commercial fill-finish, ensures quality and scalability. Formycon's expertise in development and commercialization, combined with OneSource's manufacturing, creates a synergy that can accelerate time-to-market for new biosimilars.
In conclusion, the Formycon-OneSource partnership is a strategic move to enhance global access to biosimilars through cost-effective manufacturing. It highlights the role of India as a manufacturing hub and aligns with industry trends toward affordable biologics. The partnership is expected to support Formycon's growth strategy and contribute to the broader goal of making life-saving therapies accessible to more patients worldwide.
